

MEDICAL POLICY

Medical Policy Title	Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members
Policy Number	7.01.84
Current Effective Date	August 19, 2025
Next Review Date	May 2026

Our medical policies are based on the assessment of evidence based, peer-reviewed literature, and professional guidelines practice guidelines/recommendations, including but not limited to: American College of Obstetricians and Gynecologists [ACOG], American Psychological Association [APA], American Academy of Pediatrics [AAP], Endocrine Society, and the World Professional Association for Transgender Health [WPATH]. Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract. (Link to [Product Disclaimer](#))

POLICY STATEMENT(S)

- I. Gender-affirming surgery/procedures have been shown to be a beneficial and an effective intervention for the care and transition of members with a diagnosis of gender dysphoria, and, therefore, may be considered **medically necessary/appropriate** when **ALL** the following criteria are met:
 - *Note:** Voice and communication therapy is reviewed with criteria in [Policy Statement VII](#) only and is excluded from the criteria below.
 - A. The member has reached the age of majority (18 years of age or older), unless the request is for a gender affirming mastectomy (refer to additional criteria under [Policy Statement II.C.](#));
 - B. **One (1)** letter of referral from a qualified professional who has competencies in the assessment of transgender and gender diverse people wishing gender- related medical and surgical treatment (refer to [Policy Guideline I](#)) documenting **ALL** the following:
 1. meets the DSM-5-TR diagnostic criteria for gender dysphoria (refer to the Description section);
 2. diagnosis of gender dysphoria is marked and sustained for at least 6-months;
 3. other possible causes of apparent gender dysphoria have been identified and excluded;
 4. mental health and physical conditions that could negatively impact the outcome of gender-affirming surgical/non-surgical intervention have been assessed, with risks and benefits discussed, and are reasonably well-controlled; **and**
 5. demonstrates the capacity to consent to the specific gender-affirming medical and/or surgical treatment, assessing **ALL** of the following:
 - a. the expected benefits, common risks, potential complications (e.g., new nature of some procedures and limited information available about the long-term outcomes of some procedures) associated with the surgery;

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 2 of 26

- b. impact on sexual and reproductive function, with a discussion of available reproductive options (e.g., pleasure, infertility, irreversibility of procedure); **and**
 - c. post-operative aftercare (e.g., recovery time, recovery care/needs, travel) and potential lifelong medical and/or behavioral health follow-up (e.g., breast cancer surveillance, urology);
 - C. Additional surgery-/procedure-specific policy statement(s) below are met.
- II. Gender-affirming mastectomy (with/without chest reconstruction, pectoral implants, nipple-areola preservation/reconstruction, or tattooing [i.e., nipple-areola]) is considered **medically necessary** when **ALL** the following additional criteria are met:
 - A. All criteria in Policy Statement I. are met;
 - B. The qualified professional's letter documents that the member was informed of and assessed for risk factors associated with breast cancer prior to mastectomy;
 - C. If the member is under the age of majority (under 18 years of age), **ONE** of the following additional criteria must be met:
 - 1. The qualified professional's letter documents the member's emotional and cognitive maturity required to provide informed assent for the mastectomy; **or**
 - 2. documentation that all legally responsible parties (e.g., parent[s] or guardian[s]) consent to the mastectomy and confirm the surgery aligns with the member's needs and wishes.
- III. Gender-affirming breast reconstruction (augmentation), implant or tissue extender, autologous (includes flap-based and lipofilling), including nipple/areola reconstruction and tattooing, are considered **medically necessary**, when **BOTH** of the following additional criteria are met:
 - A. All criteria in Policy Statement I. are met;
 - B. The qualified professional's letter documents that the member meets **BOTH** of the following:
 - 1. was informed of and assessed for risk factors associated with breast cancer prior to breast augmentation; **and**
 - 2. the member has completed six (6) months of continuous hormone therapy to achieve the member's desired gender affirming goals during which time breast growth was negligible, or that hormone therapy is medically contraindicated.
- IV. Gender-affirming gonadectomy (i.e., hysterectomy and/or salpingo-oophorectomy, and orchiectomy) is considered **medically necessary** when **BOTH** the following additional criteria are met:
 - A. All criteria in Policy Statement I. are met; **and**
 - B. The qualified professional's letter documents that the member has completed six (6) months of continuous hormone therapy to achieve the desired gender affirming goals, or that

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 3 of 26

hormone therapy is medically contraindicated or not clinically indicated.

V. Gender-affirming genital reconstructive surgery for the listed procedures is considered **medically necessary** when **BOTH** the following additional criteria are met:

- metoidioplasty (with/without scrotoplasty) (with/without urethral lengthening) (with/without penile and/or testicular prosthesis) (with/without colpectomy/colpocleisis)
- phalloplasty (with/without scrotoplasty) (with/without urethroplasty/urethral lengthening) (with/without penile and/or testicular prosthesis) (with/without colpectomy/colpocleisis)
- vaginoplasty (inversion, peritoneal, intestinal), may include retention of penis and/or testicle
- vulvoplasty, vaginectomy, clitoroplasty, penectomy, labiaplasty
- hair removal from the face, body, genital areas for gender affirmation of preoperative preparation (i.e., electrolysis, laser epilation) (refer to [Policy Guideline VII](#)).

A. All criteria in Policy Statement I are met; **and**

B. The qualified professional's letter documents that the member has completed six (6) months of continuous hormone therapy to achieve the desired gender affirming goals or that hormone therapy is medically contraindicated.

VI. Gender-affirming voice modification/vocal cord surgery is considered **medically appropriate** when **ALL** the following additional criteria are met and has been reviewed by a Health Plan Behavioral Health Medical Director:

A. All criteria in Policy Statement I are met;

B. The qualified professional's letter documents **ALL** of the following:

1. that the member has completed a trial of voice therapy prior to voice modification surgery (refer to [Policy Statement VII](#)).
2. there is a post-operative treatment plan that includes voice training; **and**
3. for surgery to masculinize the voice, the surgeon documents that the member has completed six (6) months of continuous hormone therapy to achieve the desired gender affirming goals or that hormone therapy is medically contraindicated. *Note: There is no evidence that feminizing hormones or GnRH agonists are an effective intervention to feminize the voice.

VII. Gender affirming feminizing or masculinizing voice and communication therapy (CPT 92507, speech therapy) is considered **medically appropriate** when **ALL** the following criteria are met and has been reviewed by a Health Plan Behavioral Health Medical Director.

***Note:** criteria in Policy Statement I are **not** required to be met.

A. The patient has reached the age of majority (18 years of age or older);

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 4 of 26

- B. The member has received **one (1)** letter of referral from a qualified professional who has competencies in the assessment of transgender and gender diverse people wishing gender-related medical and surgical treatment (refer to [Policy Guidelines I](#)) that documents the member's readiness for gender affirming care with **ALL** the following:
 - 1. meets the DSM-5-TR diagnostic criteria for gender dysphoria (refer to the Description section);
 - 2. diagnosis of gender dysphoria is marked and sustained for at least 6-months;
 - 3. demonstrates the capacity to make a fully informed decision and to consent to the specific gender-affirming care knowing the potential short- and long-term outcomes;
 - 4. other possible causes of apparent gender dysphoria have been identified and excluded;
 - 5. mental health and physical conditions that could negatively impact the outcome of gender-affirming surgical/non-surgical intervention have been assessed, with risks and benefits discussed, and are reasonably well-controlled;
 - 6. Documentation of social transition or documentation that additional assessments were conducted to offer the transgender and gender diverse (TGD) person an opportunity to consider the possible effects of not socially transitioning while still obtaining gender-affirming medical and surgical treatment; **and**
 - 7. Documentation of the member's gender-related experiences (e.g., distress, comfort, joy, self-fulfillment) and how they may fit with the specific gender affirming treatment; **and**
- C. Voice therapy (assessment, support, training) is performed by a state licensed speech language pathologist or speech therapist; **and**
- D. Continuation of therapy services is considered medically appropriate as a member makes progress, so long as the treating speech language pathologist/speech therapist documents that the member has not reached a maintenance service level in which no additional functional progress is apparent or expected to occur. For ongoing treatment to continue to be considered medically appropriate, significant improvement must be demonstrated in objective measures documented by the treating speech language pathologist or speech therapist.

VIII. Requests for gender-affirming surgeries and procedures related to secondary sex characteristics (listed below) will undergo a clinical documentation review, conducted by a Health Plan Behavioral Health Medical Director, and may be considered reconstructive and **medically appropriate** for the treatment of gender dysphoria when **ALL** the following *additional* criteria are met:

*Examples of surgeries/procedures include but are not limited to: blepharoplasty, breast liposuction, brow (reduction, augmentation, lift), cheek (implant, lipofilling), chin reshaping (osteoplastic, alloplastic [implant-based]), chondrolaryngoplasty (tracheal shave), facial bone reconstruction, facelift/mid-facelift (following alteration of underlying skeletal structure [+/- neck

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 5 of 26

lift (platysmaplasty)], hair line advancement and/or hair transplant reconstruction, hair removal not in preparation for genital reconstructive surgery, lip (upper lip shortening, lip augmentation [autologous and non-autologous]), lower jaw (reduction of mandibular angle or augmentation), monsplasty/mons reduction, rhinoplasty (+/- fillers). other liposuction or lipofilling, and other implants (pectoral, hip, gluteal, calf), uterine transplantation, penile transplantation.

A. Staged procedures (e.g., monsplasty):

1. Documentation from the treating surgeon (e.g., medical records) attesting that the requested procedure is a staged procedure of a previously approved genital reconstructive surgery, and that the procedure is medically necessary to treat the member's persistent (marked and sustained) gender dysphoria; and
2. All criteria in statements C and D below are met;

OR

B. Non-staged procedures:

1. All criteria in Policy Statement I. are met;
2. Documentation (e.g., medical records) of the member's readiness for other gender affirming surgery/non-surgical procedure(s) with ALL the *additional* criteria:
 - a. the treating qualified professional certifies the surgery/procedure is medically necessary to treat the member's persistent (marked and sustained) gender dysphoria;
 - b. the completion of a minimum of 6-months of hormone therapy to achieve the desired gender affirming goals, details that hormone therapy is medically contraindicated or that the treating provider has determined hormone therapy would have minimal effect toward the gender affirming goals.
 - c. conservative medical or surgical intervention(s) have failed or are contraindicated (e.g., diet and exercise prior to body contouring); and
 - d. embodiment goal(s) relating to gender dysphoria and how these fit with the specific gender affirming surgery/intervention requested.

C. The requested gender-affirming surgery and/or non-surgical procedure will be deemed reconstructive and medically appropriate when ALL the following *additional* criteria are met.

1. the procedure is appropriate, consistent, and required for the direct care and treatment of the member's gender dysphoria, and if the procedure is not provided, the member's condition would be adversely affected;
2. the procedure is provided in accordance with standards of generally accepted medical practice;
3. the procedure is not primarily for the convenience of the member, the member's family, the provider of services, or another provider;

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 6 of 26

4. the procedure is the most appropriate service, rendered in the most efficient and economical way and at the most economical level of care that can safely be provided;
 5. there is sufficient evidence (e.g., published peer-reviewed literature and professional practice guidelines) proving that the requested gender-affirming procedure and the way it is provided (e.g., type, frequency, extent, site, and/or duration) is as at least as effective in improving health outcomes as an established service; and
 6. when applicable, the procedure has received final approval from the appropriate government regulatory bodies (e.g., U.S. Food and Drug Administration [FDA]).
- D. Surgeries/procedures that do not meet the above criteria are considered not medically necessary.
- IX. Surgery to revise the appearance or function of a previous gender-affirming surgery due to dissatisfaction with the outcome will undergo a clinical documentation review, conducted by a Health Plan Behavioral Health Medical Director, and is considered reconstructive and **medically appropriate** when **ALL** the following additional are met:
 - A. the requested revision is required for the direct care and treatment/management of the member's gender dysphoria, and if not provided, the member would be adversely affected;
 - B. the revision is provided in accordance with standards of generally accepted medical practice;
 - C. the revision is not primarily for the convenience of the member, the provider of services, or another provider;
 - D. the revision is the most appropriate service(s), rendered in the most efficient and economical way and at the most economical level of care that can safely be provided; **and**
 - E. there is documentation detailing the member's post-operative clinically significant discomfort, distress, limitations, and/or marked functional deficit (e.g., pain or physical/mental impairment) that interferes with activities of daily living (e.g., personal, social, occupational, educational, and other important areas of functioning (refer to [Policy Guideline IV](#)).
- X. Services to reverse affirming surgery are considered **not medically necessary**, except in the case of the development of a serious medical condition necessitating reversal. Clinical records documenting the serious medical condition will be reviewed by a Health Plan Behavioral Health Medical Director, in consultation with a Physical Health Medical Director as needed.
- XI. Out-of-Network Services
 - A. Non-urgent Care or Non-emergent Care

The Plan contracts with a network of health care practitioners and providers to provide health care services for our members. Care must be received by contracted network providers to be covered by the Plan. Exceptions to this requirement are based on medical necessity and must be approved by a Health Plan Behavioral Health Medical Director.
 - B. Continuation of Care

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 7 of 26

1. For a member in an ongoing, medically necessary course of treatment with a Participating Provider who leaves the network, coverage is available for continued, ongoing treatment from this now Non-Participating Provider for up to 90 days, or, if a member is pregnant, through postpartum care. If the provider was terminated by the Health Plan due to fraud, imminent harm to patients, or final disciplinary action by a state board or agency that impairs the provider's ability to practice, continued treatment by this now Non-Participating Provider will not be covered.
2. For members new to the Health Plan and engaged in an ongoing, medically necessary course of treatment with a Non-Participating Provider, coverage is available for services performed by the Non-Participating Provider for up to 60 days from the effective date of the member's subscriber contract. The ongoing course of treatment must be for a life-threatening disease or condition or a degenerative and disabling condition or disease. Members are responsible for any in-network cost sharing applicable to these services.

RELATED POLICIES

Corporate Medical Policy

3.01.22 Gender Affirming Behavioral Health and Medical Services

7.01.105 Gender Reassignment/Gender Affirming Surgery and Treatments for Medicaid Managed Care Plan (MMCP) and Health and Recovery Plan (HARP) Members

Pharmacy Policy

This policy does not address coverage of hormone therapies (i.e., gonadotropin-releasing hormone agents/pubertal suppressants). Refer to Pharmacy Management Drug Policy # Pharmacy-63 Clinical Review Prior Authorization (CRPA) Medical for medical necessity requests.

POLICY GUIDELINE(S)

- I. Qualified Health Care Professional: WPATH Standards of Care Version 8 (SOC-8) recommends "transgender and gender diverse adults who fulfill the criteria for gender-affirming medical and surgical treatment require a single opinion for the initiation of this treatment from a professional who has competencies in the assessment of transgender and gender diverse people-related medical and surgical treatment" (Coleman 2022).

In lieu of an established, ongoing professional relationship, qualified behavioral health providers must indicate that assessments related to gender affirming intervention were conducted over an adequate/appropriate length of time to render an opinion of the member's readiness and capacity.

The qualified professional must document competency in the assessment of transgender and gender diverse people-related medical and surgical treatment with ALL the following qualifications:

- A. Is licensed by their statutory body;

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 8 of 26

- B. Holds, at a minimum, a master's degree, or equivalent training in a clinical field relevant to this role;
- C. Is able to identify and diagnose co-existing mental health or other psychosocial concerns and distinguish these from gender dysphoria, incongruence, and diversity;
- D. Is able to assess capacity to consent for treatment.

Qualified surgeon performing gender-affirming surgical procedures: WPATH SOC-8 recommends "surgeons who perform gender-affirming surgical procedures have the following credentials" (Coleman 2022):

- A. Training and documented supervision in gender-affirming procedures;
- B. Maintenance of an active practice in gender-affirming surgical procedures;
- C. Knowledge about gender diverse identities and expressions;
- D. Continuing education in the field of gender-affirmation surgery;
- E. Tracking of surgical outcomes.

Given the potential complexity and permanency of gender-affirming surgical care, the Health Plan requires specific clinical documentation that a qualified professional has obtained consent related to specific topics discussed throughout SOC-8 (e.g., impact to fertility).

- II. For individuals with considerable comorbidities or a history of severe symptoms (due to gender dysphoria, minority stress, or other behavioral health diagnosis), the provider may provide a recommendation for surgery that includes an appropriate treatment plan for addressing and mitigating these symptoms, stressors, or conditions in the pre-and post-surgical periods.
- III. Postoperative care is determined by the treating surgeon and should include sufficient medical, nursing (e.g., home care), and emotional support (e.g., family or friends) to adequately address needs in the post-operative, recovery, and healing period. For individuals having surgery remotely the patient must have medical/surgical providers in place who will be responsible for all post-surgical care including complications. A plan to use urgent/emergency care is not sufficient.
- IV. Functional impairment requiring revision surgery includes pain or other physical deficit that interferes with activities of daily living or impairs physical activity.
- V. Cases requiring a clinical peer review must be conducted by a Health Plan Behavioral Health Medical Director.
- VI. Given the complexity of phalloplasty, and current high rates of complications in comparison to other gender-affirming surgical treatments, it is not recommended this surgery be considered in youth under 18 years of age (Coleman et al 2022).
- VII. Preoperative permanent hair removal is required for any skin area (e.g., genital and body donor sites) that will be brought in contact with urine (e.g., used to construct a neourethra) or moved to reside within a partially closed cavity with the body (e.g., used to line the neovagina). See Supportive Literature section.

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 9 of 26

DESCRIPTION

Gender dysphoria, defined by the American Psychological Association (2023), is the experienced discomfort or distress related to incongruence between a person's gender identity, sex assigned at birth, gender identity, and/or primary and secondary sex characteristics. Transgender and gender diverse (TGD) is a broad and comprehensive as possible phrase describing members of the many varied communities that exist globally of people with gender identities or expression that different from the gender socially attributed to the sex assigned to them at birth. (Coleman 2022).

A clinical diagnosis of gender dysphoria is based on a comprehensive evaluation by qualified medical and behavioral health professionals. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) and International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) provide criteria and diagnostic classifications. The DSM-5 defines gender dysphoria as a marked incongruence between one's experienced/expressed gender and assigned gender of at least 6 months' duration, and provides separate developmentally appropriate criteria for children, adolescents and adults.

While gender dysphoria is still considered a mental health condition in the DSM-5-TR, the diagnosis is no longer seen as pathological or a mental disorder in the world health community (Coleman et al., 2022). In a 2023 reaffirmed policy statement, that American Academy of Pediatrics recognizes that transgender identities and diverse gender expressions do not constitute a mental disorder (Rafferty et al., 2018). Gender incongruence is recognized as a condition in the International Classification of Diseases and Related Health Problems, 11th Version of the World Health Organization (ICD-11). The ICD-11 is available for use globally as of January 2022; however, the system will require a minimum of 4 to 5 years before successfully implemented in the United States (Feinstein 2023).

Transgender health care is greater than the sum of its parts, involving holistic inter- and multidisciplinary care between endocrinology, surgery, voice and communication, primary care, reproductive health, sexual health, and mental health disciplines to support gender-affirming interventions as well as preventive care and chronic disease management. Gender-affirming care aims to support transgender and gender diverse people in addressing their social, mental, behavioral, and medical health needs while respecting their gender identity. This approach spans across the lifespan, from childhood through older adulthood, and for those experiencing uncertainty about their gender identity before or after transitioning.

The goal of psychotherapy should never be aimed at modifying a person's gender identity. Research studies have shown that the most effective treatment for gender dysphoria is gender transition, which for many may involve social transition, hormonal therapy, psychotherapy, and gender-affirming surgery. Evidence demonstrates that individuals with untreated gender dysphoria develop higher rates of depression, anxiety, substance use disorders, and suicide. Psychological techniques that attempt to treat gender dysphoria via attempts to alter the individual's gender identity or expression to one considered appropriate for the person's assigned sex (conversion and reparative therapy) have been shown to be ineffective and harmful.

Gender identities can present along a spectrum, and the expression of a person's identity may vary

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 10 of 26

quite widely amongst individuals. While the overall goal of gender-affirming care includes reduction of gender dysphoria or achieving gender congruence, gender diverse presentations may lead to individually customized surgical requests.

SUPPORTIVE LITERATURE

Major U.S. medical and mental health organizations, along with the World Health Organization (WHO), support access to age-appropriate, individualized gender-affirming care for youth and adults. Several organizations have issued expert clinical guidance with recommendations for patient-centered, evidence-based care for transgender and gender diverse people, including the American Congress of Obstetricians and Gynecologists (ACOG), American Psychological Association (APA), American Academy of Pediatrics (AAP), Endocrine Society, and the World Professional Association for Transgender Health Standards of Care for the Health of Transgender and Gender Diverse People (WPATH) (Coleman 2022).

The World Professional Association for Transgender Health (WPATH) is an international interdisciplinary professional organization dedicated to promoting evidence-based care, education, research, public policy, and respect in transgender health. WPATH upholds the highest standards of healthcare for transgender and gender diverse (TGD) people through guidelines, known as the Standards of Care (SOC). These guidelines offer clinical guidance for health professionals to better assist transgender and gender diverse people (WPATH, 2024).

The 8th version of the WPATH SOC (SOC8) was developed using an evidence-based approach to optimize patient care. The guidelines provide recommendations based on a systematic review of evidence, and an assessment of the benefits and harms of alternative care options, to help healthcare professionals offer safe and effective pathways to achieve lasting personal comfort with their gendered selves, and to maximize their overall health, psychological well-being, and self-fulfillment (Coleman 2022).

The American Academy of Child and Adolescent Psychiatry (AACAP) issues Policy Statements that promote the healthy development of children, adolescents, and families through advocacy, education, and research, and to meet the professional needs of psychiatrists. In a 2024 policy statement, the AACAP found that research consistently demonstrates that gender diverse youth who are supported to explore and/or live the gender role that is consistent with their gender identity have better mental health outcomes than those who are not. The AACAP recommends that all children and adolescents have access to multi-disciplinary, evidence-based, and trauma-informed gender-affirming health care.

According to WPATH SOC8, the goal of gender affirming medical and/or surgical treatments (GAMSTs) is to better align the body with the person's gender identity, and in appropriately selected TGD individual, the current literature supports the benefits of gender-affirming surgery (GAS). Acknowledging that GAS effects a permanent change to a person's anatomy, SOC8 states that the informed consent process needs to address the irreversibility of some procedures, the new nature of some procedures, and the limited information available about the long-term outcomes of some procedures. Informed consent includes knowledge that appropriate aftercare is essential for optimizing outcomes and it is important patients are informed about postoperative needs (including

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 11 of 26

local wound care, activity restrictions, time off from work or school, etc.). In addition, it is important the surgeon is available to provide and facilitate postoperative care, refer to specialty services, or both as needed.

Recognizing the diverse and heterogeneous community of individuals who identify as transgender and gender diverse, gender-affirming surgical interventions may be categorized along a spectrum of procedures for individuals assigned male at birth (AMAB) and assigned female at birth (AFAB). AMAB interventions may include gender-affirming breast surgery, chondrolaryngoplasty/vocal cord surgery, orchiectomy, vagino/vulvoplasty, voice therapy. AFAB interventions may include gender-affirming chest surgery, hysterectomy/oophorectomy, metoidioplasty (including testicular prosthesis), phalloplasty (including placement of testicular/penile prosthetic).

Given the complexity of phalloplasty, and current high rates of complications in comparison to other gender-affirming surgical treatments, it is not recommended this surgery be considered in youth under 18 years of age (Coleman 2022). Gender affirming surgery prior to the age of 18, or the legal age to give consent, is not fully supported by professional societies.

The Endocrine Society suggests that clinicians delay gender-affirming genital surgery involving gonadectomy and/or hysterectomy until the patient is at least 18 years old or legal age of majority (Hembree 2017).

The American Pediatric Association acknowledges that lack of clearly defined eligibility criteria for surgical interventions among adolescents and determination is made on a case-by-case basis (Rafferty 2018).

In a 2020 position statement, the American Psychiatric Association (APA) supports access to affirming and supportive treatment for trans and gender diverse youth and their families and, when indicated, puberty suppression and medical transition support. Gender-affirming surgeries may follow in later adolescence or young adulthood.

Hormone Therapy

The Endocrine Society issued guideline resources on endocrine treatment of gender dysphoric/gender incongruent persons (Hembree 2017). The Endocrine Society advises that only trained mental health professionals (MHP) should diagnosis gender dysphoria and that decisions regarding the social transition of prepubertal youths with gender dysphoria/gender incongruence are made with the assistance of an MHP or another experienced professional. Additionally, the guideline:

- recommends against puberty blocking and gender-affirming hormone treatment in pre-pubertal children with gender dysphoria/gender incongruence;
- advises that clinicians approve genital gender-affirming surgery only after completion of at least 1 year of consistent and compliant hormone treatment, unless hormone therapy is not desired or medically contraindicated;
- advises that the clinician responsible for endocrine treatment and the primary care provider ensure appropriate medical clearance of the individual for genital gender-affirming surgery.

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 12 of 26

Voice and Communication

Voice and communication therapy may help to alleviate gender dysphoria. Although not every TGD person experiences challenges with or wants professional support for their voice and communication, specialists (e.g., speech-language pathologists, speech therapists) can educate and support behavioral changes such as pitch, voice quality, facial expression, gesture, respiration, and projection. Two types of laryngeal surgeries are relevant for TGD populations: those for raising voice pitch (e.g., glottoplasty with retro-displacement of the anterior commissure, cricothyroid approximation [CTA], feminization laryngoplasty, laser-assisted voice adjustment [LAVA]) (Coleman 2022).

Hair (Removal or Restoration)

Hair removal may be an important part of gender affirmation for some individuals; however, it is necessary for genital gender affirming surgery (GAS). Surgeons performing genital GAS require preoperative permanent hair removal from any skin area that will either be brought into contact with urine (e.g., used to construct a neourethra) or be moved to reside within a partially closed cavity within the body (e.g., used to line the neovagina) (Zhang 2016; Coleman 2022). Genital GAS often utilizes hair-bearing flaps (e.g., forearm, thigh) for reconstruction of the genitals to match an individual's desired gender expression. To prevent the unwanted hair growth and associated complications (e.g., urinary retention or obstruction, and infection), genital GAS has become a recognized indication for hair removal (Zhang 2016).

For hair removal not associated with genital GAS, there are widely available and easily accessible methods to remove unwanted hair (e.g., shaving, waxing, depilatories, threading, laser, and electrolysis) (AAD 2023).

Platelet rich plasma (PRP) and hyperbaric oxygen therapy (HBOT) are being investigated as adjuvant treatment options for people with androgenetic alopecia (AGA). Both lack evidence-based peer-reviewed literature, and both lack FDA clearance/authorization for treatment of AGA.

Uterine Transplantation

Uterus transplantation is a complex, multi-stage process involving a living or deceased donor, recipient, and genetic partner. It is the first organ transplantation procedure intended to be temporary, concluding with graft hysterectomy to avoid the need for lifelong immunosuppression once childbearing is deemed complete. Pregnancy in the transplanted uterus is achieved through in-vitro fertilization (IVF) and embryo transfer (Johannesson 2020).

Absolute uterine factor infertility (AUI) is a condition in which an individual is unable to achieve pregnancy due to an absent or non-functioning uterus due to congenital, surgical, anatomical, or acquired factors that prevent embryo implantation and term pregnancy. Uterine transplantation is currently being investigated as a childbearing option that is an alternative to existing family planning pathways, including adoption, foster parenting, and gestational carrier pregnancy. Literature has explored the implications of uterus transplantation in transgender women, identifying several theoretical medical issues in genetic males meriting further investigation (Lefkowitz 2013; Jones 2021). The cross-sectional study of 182 transgender woman found that 168 (92%) of respondents

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 13 of 26

indicated a transplant would help them feel like more of a woman, especially with the ability to menstruate (Jones 2021).

WPATH SOC-8 suggests that health care professionals caring for individuals with intersexuality and congenital infertility introduce them and their families, early and gradually, to the various alternative options of parenthood (Coleman 2023). WPATH acknowledges the preliminary success of uterus transplantation in people with Mullerian agenesis and that there is no protocol to date that avoids exposure of the developing fetus to the risks associate with the medications used to avoid transplant rejection. Although listed among gender-affirming procedures in Appendix E, SOC-8 does not include uterine transplantation in the list of medically necessary gender-affirming interventions in Statement 2.1.

The American College of Obstetricians and Gynecologists has not published a clinical practice guideline for uterine transplantation; however, in their Committee Opinion (Number 728) on müllerian agenesis (2020) indicates that while live births have resulted from uterine transplantation, "given limited data, this procedure currently is considered experimental and is not widely available."

Penile Transplantation

Penile transplantation using vascularized composite allografts is an emerging technique to treat genital loss. Szafran and colleagues (2018) conducted a review of penile transplantation in the United States, reporting that the initial concept for the development of a penile transplant program at the Johns Hopkins Medical Institutions began in November 2013 with an initial aim to restore functional status to combat war veterans who sustained genital injuries. Massachusetts General Hospital performed the first successful penile transplantation in May 2016.

WPATH SOC-8 lists penile transplantation among gender-affirming procedures in Appendix E, SOC-8 does not include penile transplantation in the list of medically necessary gender-affirming interventions in Statement 2.1.

According to de Haseth and colleagues (2023), the ongoing quest to surgically create the (nearly) ideal neophallus in transgender men has led to the continuous development of transgender medicine and the proposed introduction of penis transplantation. Given technical and ethical issues that arise when developing this treatment, these authors conducted an empirical ethics study to extract ethical considerations among different stakeholder groups regarding penile transplantation surgery in transgender men and to define preliminary clinical recommendations. The authors concluded that, "should the technical side of this treatment option develop, further research in the ethical field of penile transplantation for transgender men is recommended."

PROFESSIONAL GUIDELINE(S)

As detailed above.

REGULATORY STATUS

Guidance issued by the New York State Department of Financial Services prohibits the Health Plan from denying benefits for medically necessary treatment that is otherwise covered by a health

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 14 of 26

insurance contract, solely on the basis that the treatment is for gender dysphoria. Furthermore, the New York Insurance Law requires that Health Plan contracts providing coverage for inpatient hospital care and/or physician services must also provide coverage for the diagnosis and treatment of mental, nervous, or emotional disorders or ailments.

CODE(S)

- Codes may not be covered under all circumstances.
- Code list may not be all inclusive (AMA and CMS code updates may occur more frequently than policy updates).
- (E/I)=Experimental/Investigational
- (NMN)=Not medically necessary/appropriate

CPT Codes

Code	Description
11950	Subcutaneous injection of filling material (e.g., collagen); 1 cc or less
11951	Subcutaneous injection of filling material (e.g., collagen); 1.1 to 5.0 cc
11952	Subcutaneous injection of filling material (e.g., collagen); 5.1 to 10.0 cc
11954	Subcutaneous injection of filling material (e.g., collagen); over 10.0 cc
15769	Grafting of autologous soft tissue, other, harvested by direct excision (e.g., fat, dermis, fascia)
15771	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate
15772	each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)
15773	Grafting of autologous fat, harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate
15774	each additional 25 cc or less injectate, or part thereof (List separately in addition to the code for primary procedure)
15775	Punch graft for hair transplant; 1 to 15 punch grafts (as part of forehead feminization surgery)
15776	Punch graft for hair transplant; more than 15 punch grafts (as part of forehead feminization surgery)
15820	Blepharoplasty, lower eyelid;
15821	Blepharoplasty, lower eyelid; with extensive herniated fat pad
15822	Blepharoplasty, upper eyelid;
15823	Blepharoplasty, upper eyelid; with excessive skin weighting down lid
15824	Rhytidectomy; forehead

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 15 of 26

Code	Description
15825	Rhytidectomy; neck with platysmal tightening (platysmal flap, P-flap)
15826	Rhytidectomy; glabellar frown lines
15828	Rhytidectomy; cheek, chin, and neck
15830	Excision, excessive skin, and subcutaneous tissue (includes lipectomy); abdomen, infraumbilical panniculectomy
15832	thigh
15833	leg
15834	hip
15835	buttock
15836	arm
15837	forearm or hand
15838	submental fat pad
15839	other area
15847	Excision, excessive skin, and subcutaneous tissue (includes lipectomy), abdomen (e.g., abdominoplasty) (includes umbilical transposition and fascial plication) (List separately in addition to code for primary procedure)
15876	Suction assisted lipectomy; head and neck
15877	Suction assisted lipectomy; trunk
15878	Suction assisted lipectomy; upper extremity
15879	Suction assisted lipectomy; lower extremity
17380	Electrolysis epilation, each 30 minutes
19303	Mastectomy, simple, complete
19316	Mastopexy
19318	Breast reduction
19325	Breast augmentation with implant
21120	Genioplasty; augmentation (autograft, allograft, prosthetic material)
21123	Genioplasty; sliding, augmentation with interpositional bone grafts (includes obtaining autografts)
21193	Reconstruction of mandibular rami, horizontal, vertical, C, or L osteotomy; without bone graft
21208	Osteoplasty, facial bones; augmentation (autograft, allograft, or prosthetic implant)
21209	Osteoplasty, facial bones; reduction
21270	Malar augmentation, prosthetic material

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 16 of 26

Code	Description
30400	Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip
30410	Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip
30420	Rhinoplasty, primary; including major septal repair
30430	Rhinoplasty, secondary; minor revision (small amount of nasal tip work)
30435	Rhinoplasty, secondary; intermediate revision (bony work with osteotomies)
30450	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies)
30462	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip, septum, osteotomies
30465	Repair of nasal vestibular stenosis (e.g., spreader grafting, lateral nasal wall reconstruction)
31599	Unlisted procedure, larynx (can be used for reduction of thyroid cartilage)
40500	Vermilionectomy (lip shave), with mucosal advancement
53410	Urethroplasty, 1-stage reconstruction of male anterior urethra
53420	Urethroplasty, 2-stage reconstruction or repair of prostatic or membranous urethra; first stage
53430	Urethroplasty, reconstruction of female urethra
54120	Amputation penis; partial
54125	Amputation penis, complete
54400	Insertion of penile prosthesis; non-inflatable (semi-rigid)
54401	Insertion of penile prosthesis; inflatable (self-contained)
54405	Insertion of multi-component, inflatable penile prosthesis, including placement of pump, cylinders, and reservoir
54408	Repair of component(s) of a multi-component, inflatable penile prosthesis
54410	Removal and replacement of all component(s) of a multi-component, inflatable penile prosthesis at the same operative session
54411	Removal and replacement of all components of a multi-component inflatable penile prosthesis through an infected field at the same operative session, including irrigation and debridement of infected tissue
54416	Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis at the same operative session
54417	Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis through an infected field at the same operative session, including irrigation and debridement of infected tissue
54520	Orchiectomy, simple (including subcapsular), with or without testicular prosthesis,

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 17 of 26

Code	Description
	scrotal or inguinal approach
54522	Orchiectomy, partial
54660	Insertion of testicular prosthesis (separate procedure)
55175	Scrotoplasty; simple
55180	Scrotoplasty, complicated
55899	Unlisted procedure, male genital system (*when used to report metoidioplasty/ phalloplasty)
55970	Intersex surgery, male to female
55980	Intersex surgery, female to male
56800	Plastic repair introitus
56805	Clitoroplasty for intersex state
57106	Vaginectomy, partial removal of vaginal wall
57110	Vaginectomy, complete removal of vaginal wall;
58150	Total abdominal hysterectomy, (corpus and cervix), with or without removal of tube(s), with or without removal of ovary(s)
58152	with colpo-urethrocystopexy (e.g., Marshall-Machetti-Krantz, Burch)
58180	Supracervical abdominal hysterectomy (subtotal hysterectomy), with or without removal of tube(s), with or without removal of ovary(s)
58260	Vaginal hysterectomy, for uterus 250 g or less;
58262	for uterus 250 g or less; with removal of tube(s), and/or ovary(s)
58263	with removal of tube(s), and/or ovary(s), with repair of enterocele
58267	with colpo-urethrocystopexy (Marshall-Marchetti-Krantz type, Pereyra type) with or without endoscopic control
58270	with repair of enterocele
58275	with total or partial vaginectomy;
58280	with total or partial vaginectomy;
58285	Vaginal hysterectomy, radical (Schauta type operation)
58290	for uterus greater than 250 g;
58291	for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)
58292	with removal of tube(s) and/or ovary(s), with repair of enterocele
58294	with repair of enterocele
58720	Salpingo-oophorectomy, complete or partial, unilateral, or bilateral (separate procedure)

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 18 of 26

Code	Description
58940	Oophorectomy, partial or total, unilateral, or bilateral;
58953	Bilateral salpingo-oophorectomy with omentectomy, total abdominal hysterectomy and radical dissection for debulking;
67900	Repair of brow ptosis (supraciliary, mid-forehead or coronal approach)
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual
92508	Treatment of speech, language, voice, communication, and/or auditory processing disorder; group, 2 or more individuals

Copyright © 2025 American Medical Association, Chicago, IL

HCPCS Codes

Code	Description
Not Applicable	

ICD10 Codes

Code	Description
F64.0 - F64.9	Gender identity disorders (code range)
Z87.890	Personal history of sex reassignment
There is no ICD-10 code for gender incongruence.	

REFERENCES

Agana MG, et al. Caring for the transgender adolescent and young adult: current concepts of an evolving process in the 21st century. Dis Mon. 2019 Sep;65(9):303-356.

American Academy of Child and Adolescent Psychiatry (AACAP) [Internet]. Policy Statements [accessed 2025 Aug 19]. Available from:

https://www.aacap.org/AACAP/Policy_Statements/Home.aspx

American Academy of Dermatology Association (AAD) [Internet]. 6 ways to remove unwanted hair. 2023 Sep 07 [accessed 2025 Aug 19]. Available from: <https://www.aad.org/public/everyday-care/skin-care-basics/hair/remove-unwanted-hair>

American Academy of Pediatrics. Policy Statement 2018, reaffirmed 2023. Refer to Rafferty et al. reference.

American College of Obstetricians and Gynecologists. Health care for transgender and gender diverse individuals: ACOG Committee Opinion, No. 823. Obstet Gynecol. 2021;137(3):e75–88. PMID:

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 19 of 26

33595253

American College of Obstetricians and Gynecologists. Committee on Adolescent Health Care. ACOG Committee Opinion No. 728: Müllerian Agenesis: Diagnosis, Management, And Treatment. *Obstet Gynecol*. 2018 Jan;131(1):p e35-e42. PMID: 29266078.

American Electrology Association. Essential Electrolysis facts. 2022 [Live hair-free with electrolysis | American Electrology Association] accessed 11/30/22.

American Electrology Association [Internet]. What is electrolysis? 2025 [accessed 2025 Aug 19]. Available from: <https://www.electrology.com/faqs-about-permanent-hair-removal/>

American Psychiatric Association: Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR). Washington, DC, American Psychiatric Association, 2022.

American Psychiatric Association: Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Washington, DC, American Psychiatric Association, 2013.

American Psychological Association. Guidelines for psychological practice with transgender and gender nonconforming people. *American Psychologist*. 2015 Dec;70(9):832-864.

American Psychiatric Association [Internet]. APA official actions. Position statement on treatment of transgender (trans) and gender diverse youth. 2020 [accessed 2025 Aug 19]. Available from: <https://www.psychiatry.org/getattachment/dab09460-02d5-4693-aa54-7f7bf9f79d63/Position-Client-Provider.pdf>

American Psychological Association (APA) Council of Representatives [Internet]. APA policy statement on affirming evidence-based inclusive care for transgender, gender diverse, and nonbinary individuals, addressing misinformation, and the role of psychological practice and science. 2024 Feb [accessed 2025 Aug 19]. Available from: <https://www.apa.org/about/policy/transgender-nonbinary-inclusive-care>

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing, 2013.

Andréasson M, et al. Patient-reported outcome measures used in gender confirmation surgery: a systematic review. *Plast Reconstr Surg*. 2018 Apr;141(4):1026-1039.

Aydin D, et al. Transgender surgery in Denmark from 1994 to 2015: 20-year follow-up study. *J Sex Med*. 2016 April;13(4):720-725.

Bellinga RJ, et al. Technical and clinical considerations for facial feminization surgery with rhinoplasty and related procedures. *JAMA Facial Plast Surg*. 2017 May 1;19(3):175-181.

Bradley SJ and Zucker KJ. Gender identity disorder: A review of the past 10 years. *J Am Acad Child Adolesc Psychiatry*. 1997;36(7):872-80.

Brown SK, et al. Addition of Wendler glottoplasty to voice therapy improves trans female voice outcomes. *Laryngoscope*. 2021 Jul;131(7):1588-1593. Epub 2020 Aug 26.

Capitán L, et al. Facial feminization surgery: simultaneous hair transplant during forehead

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 20 of 26

reconstruction. *Plast Reconstr Surg*. 2017 Mar;139(3):573-584.

Casado JC, et al. Wendler glottoplasty and voice-therapy in male-to-female transsexuals: results in pre and post-surgery assessment. *Acta Otorrinolaringol Esp*. 2016 Mar-Apr;67(2):83-92.

Castellano E, et al. Quality of life and hormones after sex reassignment surgery. *J Endocrinol Invest*. 2015 Dec;38(12):1373-1381.

Cohen-Kettenis PT, et al. Transsexualism: a review of etiology, diagnosis, and treatment. *J Psychosom Res*. 1999; 46(4):315-333.

Cohen WA, et al. Female-to-male transgender chest contouring: A systematic review of outcomes and knowledge gaps. *Ann Plast Surg*. 2019 Nov;83(5):589-593.

Coleman E, et al. Standards of care for the health of transgender and gender diverse people, Version 8. *Inter J of Transgender Health*. 2022 Sep;23(S1): S1-S260.

de Blok CJM, et al. Breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study. *J Clin Endocrinol Metab*. 2018 Feb 1;103(2):532-538.

de Blok CJM, et al. Sustained breast development and breast anthropometric changes in 3 years of gender-affirming hormone treatment. *J Clin Endocrinol Metab*. 2021 Jan 23;106(2):e782-e790.

de Hase KB, et al. Ethical consideration regarding penis transplantation surgery in transgender men – an empirical ethics study. *Sex Med*. 2023 Aug;11(4):qfad041. PMID 37720817

Dy GW, et al. Presenting complications to a reconstructive urologist after masculinizing genital reconstructive surgery. *Urology*. 2019 Oct;132:202-206.

Eldh J, et al. Long-term follow up after sex reassignment surgery. *Scand J Plast Reconstr Surg Hand Surg*. 1997;31(1):39-45.

Endocrine Society [Internet]. Endocrine Society Statement in Support of Gender-Affirming Care. 2024 May 08 [accessed 2025 Aug 19]. Available from: <https://www.endocrine.org/news-and-advocacy/news-room/2024/statement-in-support-of-gender-affirming-care>

Goa JL, et al. Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics. *J Am Academy of Dermatol*. 2023 Oct 1;89(4):774-783.

Gelfer MP and Tice RM. Perceptual and acoustic outcomes of voice therapy for male-to-female transgender individuals immediately after therapy and 15 months later. *J Voice*. 2013 May;27(3):335-47.

Gray ML and Courey MS. Transgender voice and communication. *Otolaryngol Clin North Am*. 2019 Aug;52(4):713-722.

Gupta AK, et al. The efficacy of platelet rich plasma in the field of hair restoration and facial aesthetics – A systematic review and meta-analysis. *J Cutaneous and Med Surg*. 2019;23:185–203.

Hancock AB and Garabedian LM. Transgender voice and communication treatment: a retrospective chart review of 25 cases. *Int J Lang Commun Disord*. 2013 Jan;48(1):54-65.

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 21 of 26

Hembree WC, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2009 Sep;94(9):3132-54.

Hembree WC, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2017 Nov 13;102(11):1-35.

Hepp U, et al. A. Psychiatric comorbidity in gender identity disorder. *J Psychosom Res*. 2005;58(3):259-61.

Irwig MS, et al. Effects of testosterone on the transgender male voice. *Andrology*. 2017 Jan;5(1):107-112.

Jones BP, et al. Perceptions and motivations for uterus transplant in transgender women. *JAMA Netw Open*. 2021 Jan 04; 4(1): e2034561. PMID 33471119.

Kattari SK, et al. Exploring the relationship between transgender-inclusive providers and mental health outcomes among transgender/gender variant people. *Social Work in Health Care* 2016 Mar 17;55(8):635–650.

Kelly V, et al. Effects of gender-confirming pitch-raising surgery in transgender women a long-term follow-up study of acoustic and patient-reported data. *J Voice*. 2019 Sep;33(5):781-791.

Kim HT. A new conceptual approach for voice feminization: 12 years of experience. *Laryngoscope*. 2017 May;127(5):1102-1108.

Kim HT. Vocal feminization for transgender women: current strategies and patient perspectives. *Int J. Gen Med* 2020 Feb 12;13:43-52.

Klein C, et al. Sexual functioning in transsexuals following hormone therapy and genital surgery: a review. *J Sex Med* .2009 Nov;6(11):2922-39.

Landen M, et al. Factors predictive of regret in sex reassignment. *Acta Psychiatr Scand* 1998;97(4):284-9.

Lawrence AA. Factors associated with satisfaction or regret following male-to-female sex reassignment surgery. *Arch Sex Behav*. 2003 Aug;32(4):299-315.

Lawrence AA. Sexuality before and after male-to-female sex reassignment surgery. *Arch Sex Behav*. 2005 Apr;34(2):147-66.

Lee MS, et al. Association between gender-affirming hair removal and mental health outcomes. *JAMA. Derm* 2021 Jul 21;157(9):1120-1122.

Lefkowitz A, et al. Ethical considerations in the era of the uterine transplant: an update of the Montreal Criteria for the Ethical Feasibility of Uterine Transplantation. *Fertil Steril*. 2013 Oct;100(4):924-6. PMID 23768985

Lepselter & Elman. Biological and clinical aspects in laser hair removal. *Journal of Derm Treat*. 2004 May;15(2):72-83.

Levy JA, et al. Male-to-female gender reassignment surgery: An institutional analysis of outcomes,

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 22 of 26

short-term complications, and risk factors for 240 patients undergoing penile-inversion vaginoplasty. *Urology*. 2019 Sep;131:228-233.

Lindqvist EK, et al. Quality of life improves early after gender reassignment surgery in transgender women. *Eur J Plast Surg*. 2017;40(3):223-226.

Lobato MI, et al. Follow-up of sex reassignment surgery in transsexuals: a Brazilian cohort. *Arch Sex Behav*. 2006 Dec;35(6):711-5.

Lopez CM, et al. Trends in the use of puberty blockers among transgender children in the United States. *J Pediatr Endocrinol Metab*. 2018 Jun 27;31(6):665-670.

Manrique OJ, et al. Complications and patient-reported outcomes in male-to-female vaginoplasty-where we are today: a systematic review and meta-analysis. *Ann Plast Surg*. 2018 Jun;80(6):684-691.

Marks DH, et al. Hair reduction for transgender persons what dermatologists should know and how they can help. *JAMA Derm*. 2019 May;155(5):525-526.

Massie JP. Predictors of patient satisfaction and postoperative complications in penile inversion vaginoplasty. *Plast Reconstr Surg*. 2018 Jun;141(6):911e-921e.

Mastronikolis NS, et al. Wendler glottoplasty: an effective pitch raising surgery in male-to-female transsexuals. *J Voice*. 2013 Jul;27(4):516-22.

Meister J, et al. Pitch elevation in male-to-female transgender persons-the Würzburg approach. *J Voice*. 2017 Mar;31(2):244.e7-244.e15.

Meriggiola MC, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline: commentary from a European perspective. *Eur J Endocrinol*. 2010 May;162(5):831-3.

Midence K and Hargreaves I. Psychosocial adjustment in male-to-female transsexuals: an overview of the research evidence. *J Psychol*. 1997;131(6):602-14.

Monstrey S, et al. Surgical therapy in transsexual patients: a multi-disciplinary approach. *Acta Chir Belg*. 2001;101(5):200-9.

Morrison SD, et al. Prospective quality-of-life outcomes after facial feminization surgery: an international multicenter study. *Plast Reconstr Surg*. 2020 Jun;145(6):1499-1509.

New York Electrolysis Association [Internet]. What is Electrolysis? 2025 [accessed 2025 Aug 19]. Available from: <https://www.electrolysisnyea.org/about-electrolysis-hair-removal.php>

Ngaage LM, et al. Health insurance coverage of gender-affirming top surgery in the United States. *Plast Reconstr Surg*. 2019 Oct;144(4):824-833.

Nolan IT, et al. The role of voice therapy and phonosurgery in transgender vocal feminization. *J Craniofac Surg*. 2019 Jul;30(5):1368-1375.

Nygren U, et al. Effects on voice fundamental frequency and satisfaction with voice in trans men

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 23 of 26

during testosterone treatment-a longitudinal study. *J Voice*. 2016 Nov;30(6):766.e23-766.e34.

Olson-Kennedy J, et al. Chest reconstruction and chest dysphoria in transmasculine minors and young adults: comparisons of nonsurgical and postsurgical cohorts. *JAMA Pediatr*. 2018 May 1;172(5):431-436.

Olson-Kennedy J, et al. Histrelin implants for suppression of puberty in youth with gender dysphoria: A comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA). *Transgend Health*. 2021 Feb 15;6(1):36-42.

Papadopoulos NA, et al. Male-to-female sex reassignment surgery using the combined technique leads to increased quality of life in a prospective study. *Plast Reconstr Surg* 2017 Aug;140(2):286-294.

Pasternak K and Francis DO. An update on treatment of voice-gender incongruence by otolaryngologists and speech-language pathologists. *Curr Opin Otolaryngol Head Neck Surg*. 2019 Dec;27(6):475-481.

Pittman TA and Economides JM. Preparing for facial feminization surgery: timing. *Facial Plast Surg Clin North Am*. 2019 May;27(2):191-197.

Raffaini M, et al. Full facial feminization surgery: patient satisfaction assessment based on 180 procedures involving 33 consecutive patients. *Plast Reconstr Surg*. 2016 Feb;137(2):438-48.

Rafferty J, AAP committee on psychosocial aspects of child and family health, AAP committee on adolescence, AAP section on lesbian, gay, bisexual, and transgender health, and wellness. Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. *Pediatrics*. 2018;142(4):e20182162.

Salgado CJ, et al. Gender reassignment: feminization and masculinization of the neck. *Clin Plast Surg*. 2018 Oct;45(4):635-645.

Schlatterer K, et al. Multistep treatment concept of transsexual patients. *Exp Clin Endocrin Diab*. 1996;104(6):413-9.

Smith YL, et al. Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals. *Psychol Med*. 2005;35(1):89-99.

Smith YL, et al. Adolescents with gender identity disorder who were accepted or rejected for sex reassignment surgery: a prospective follow-up study. *J Am Acad Child Adolesc Psychiatry*. 2001 Apr;40(4):472-81.

Sohn M, et al. Gender identity disorders: diagnostic and surgical aspects. *J Sex Med*. 2007 Sep;4(5):1193-207.

Song TE and Jiang N. Transgender phonosurgery: a systematic review and meta-analysis. *Otolaryngol Head Neck Surg*. 2017 May;156(5):803-808.

Sutcliffe PA, et al. Evaluation of surgical procedures for sex reassignment: a systematic review. *J Plast Reconstr Aesthet Surg*. 2009 Mar;62 (3):294-306.

Tebbens M, et al. Gender-affirming hormone treatment induces facial feminization in transwomen

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 24 of 26

and masculinization in transmen: quantification by 3D scanning and patient-reported outcome measures. *J Sex Med*. 2019 May;16(5):746-754.

Therattil PJ, et al. Esthetic reduction of the thyroid cartilage: a systematic review of chondrolaryngoplasty. *JPRAS Open*. 2019 Aug 2;22:27-32.

U.S. Food & Drug Administration (FDA) [Internet]. Consumer updates. Hyperbaric oxygen therapy: get the facts. 2021 July 26 [accessed 2025 Aug 19]. Available from:

<https://www.fda.gov/consumers/consumer-updates/hyperbaric-oxygen-therapy-get-facts>

Van Damme S, et al. The effectiveness of pitch-raising surgery in male-to-female transsexuals: a systematic review. *J Voice*. 2017 Mar;31(2):244.e1-244.e5.

Van der Sluis WB, et al. Long-term follow-up of transgender women after secondary intestinal vaginoplasty. *J Sex Med*. 2016 April;13(4):702-710.

Verma K. A study to compare the efficacy of platelet-rich plasma and minoxidil therapy for the treatment of androgenetic alopecia. *Inter J of Trichology*. 2019 Mar-Apr;11(2):68–79. PMID: 31007475.

Weigert R, et al. Patient satisfaction with breasts and psychosocial, sexual, and physical well-being after breast augmentation in male-to-female transsexuals. *Plast Reconstr Surg*. 2013 Dec;132(6):1421-9.

Weinforth G, et al. Quality of life following male-to-female sex reassignment surgery. *Dtsch Arztebl. Int* 2019 Apr 12;116(15):253-260.

Wernick JA, et al. A systematic review of the psychological benefits of gender-affirming surgery. *Urol Clin North Am*. 2019 Nov;46(4):475-486.

Wierckx K, et al. Quality of life and sexual health after sex reassignment surgery in transsexual men. *J Sex Med*. 2011 Dec;8(12):3379-88.

World Professional Association for Transgender Health (WPATH) Standards of Care. Refer to Coleman et al. reference.

World Professional Association for Transgender Health (WPATH) [Internet]. Position statement on medical necessity of treatment, sex reassignment, and insurance coverage in the U.S.A. 2016 Dec 21 [accessed 2025 Aug 19]. Available from: <https://www.wpath.org/newsroom/medical-necessity-statement>

Yuan et al. Comparison of permanent hair removal procedures before gender-affirming vaginoplasty: why we should consider laser hair removal as a first-line treatment for patients who meet criteria. *J Sex Med*. 2022 Oct;10(5):100545.

Zhang WR, et al. Laser hair removal for genital gender affirming surgery. *Transl Androl Urol*. 2016 Jun;5(3):381-387.

SEARCH TERMS

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 25 of 26

Not Applicable

CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)

[Gender Dysphoria and Gender Reassignment Surgery \(NCD 140.9\)](#) [accessed 2025 Aug 19]

[Gender Dysphoria and Gender Reassignment Surgery National Coverage Analysis \(NCA\) \(CAG-00446N\)](#) [accessed 2025 Aug 19]

[Medicare Claims Processing Manual. Chapter 32 - Billing Requirements For Special Services. Transmittal 240- Special Instructions For Certain Claims With A Gender/Procedure Conflict. \(Rev. 12571; Issued 04/11/24\)](#) [accessed 2025 Aug 19]

PRODUCT DISCLAIMER

- Services are contract dependent; if a product does not cover a service, medical policy criteria do not apply.
- If a commercial product (including an Essential Plan or Child Health Plus product) covers a specific service, medical policy criteria apply to the benefit.
- If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.
- If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.
- If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.

POLICY HISTORY/REVISION

Committee Approval Dates

10/28/10, 12/08/11, 10/25/12, 10/24/13, 10/23/14, 12/10/15, 12/8/16, 04/26/18, 04/24/19, 04/23/20, 12/10/20, 02/17/21, 03/24/22, 12/22/22, 02/22/24, 08/22/24, 05/22/25

Date	Summary of Changes
10/07/25	<ul style="list-style-type: none">• Policy edit, intent unchanged, to add an example to the non-inclusive list of surgeries and procedures related to secondary sex characteristics for clarity.
09/12/25	<ul style="list-style-type: none">• Policy edit, intent unchanged, to correct the location of several "refer to" statements.
08/19/25	<ul style="list-style-type: none">• Effective date for implementation of criteria updated in May 2025.
05/22/25	<ul style="list-style-type: none">• Annual review and updated criteria, with policy intent changes, to comply

Medical Policy: Gender Affirming Surgery and Treatments for Commercial and Medicare Advantage Members

Policy Number: 7.01.84

Page: 26 of 26

	with New York State Mandate.
01/01/25	<ul style="list-style-type: none">• Summary of changes tracking implemented.
10/28/10	<ul style="list-style-type: none">• Original effective date